Search Results
You are looking at 1 - 3 of 3 items for
- Author: Rudolf Arnold x
- Refine by access: All content x
Search for other papers by Martin Gotthardt in
Google Scholar
PubMed
Search for other papers by Martin P Béhé in
Google Scholar
PubMed
Search for other papers by Julia Grass in
Google Scholar
PubMed
Search for other papers by Artur Bauhofer in
Google Scholar
PubMed
Search for other papers by Anja Rinke in
Google Scholar
PubMed
Search for other papers by Meike L Schipper in
Google Scholar
PubMed
Search for other papers by Marc Kalinowski in
Google Scholar
PubMed
Search for other papers by Rudolf Arnold in
Google Scholar
PubMed
Search for other papers by Wim J G Oyen in
Google Scholar
PubMed
Search for other papers by Thomas M Behr in
Google Scholar
PubMed
Gastrin receptor scintigraphy (GRS) is a new imaging method primarily developed for the detection of metastases of medullary thyroid carcinoma (MTC). As gastrin-binding CCK2 receptors are also expressed on a variety of other neuroendocrine tumours (NET), we compared GRS to somatostatin receptor scintigraphy (SRS) in patients with NET. SRS and GRS were performed within 21 days in a series of 60 consecutive patients with NET. GRS was directly compared with SRS. If lesions were visible on GRS but not detectable by SRS, other imaging modalities (MRI, CT) and follow-up were used for verification. Of the 60 evaluable patients, 51 had carcinoid tumours, 3 gastrinomas, 2 glucagonomas, 1 insulinoma and 3 paragangliomas. The overall tumour-detection rate was 73.7% for GRS and 82.1% for SRS. In the 11 patients with negative SRS, GRS was positive in 6 (54.5%). Based on the number of tumour sites detected and the degree of uptake, GRS performed better than SRS in 13 patients (21.7%), equivalent images were obtained in 18 cases (30.0%) and SRS performed better in 24 (40.0%) cases. In six of the SRS positive patients, 18 additional sites of tumour involvement could be detected. Overall, GRS detected additional tumour sites in 20% of the patients. Localisation of the primary tumours or their functional status had no influence on the outcome of imaging. GRS should be performed in selected patients as it may provide additional information in patients with NET with equivocal or absent somatostatin uptake.
Search for other papers by Larry K Kvols in
Google Scholar
PubMed
Search for other papers by Kjell E Oberg in
Google Scholar
PubMed
Search for other papers by Thomas M O'Dorisio in
Google Scholar
PubMed
Search for other papers by Pharis Mohideen in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Rudolf Arnold in
Google Scholar
PubMed
Search for other papers by Ke Hu in
Google Scholar
PubMed
Search for other papers by Yilong Zhang in
Google Scholar
PubMed
Search for other papers by Gareth Hughes in
Google Scholar
PubMed
Search for other papers by Lowell Anthony in
Google Scholar
PubMed
Search for other papers by Bertram Wiedenmann in
Google Scholar
PubMed
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst1,2,3) and sst5. Because of this binding profile, pasireotide may offer symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR. This was a phase II, open-label, multicenter study of pasireotide in patients with advanced NET whose symptoms of carcinoid syndrome (diarrhea/flushing) were inadequately controlled by octreotide LAR. Patients received s.c. pasireotide 150 μg twice daily (bid), escalated to a maximum dose of 1200 μg bid until a clinical response was achieved. Forty-four patients were evaluated for efficacy and 45 for tolerability. Pasireotide 600–900 μg s.c. bid effectively controlled the symptoms of diarrhea and flushing in 27% of patients. Evaluation of tumor response in 23 patients showed 13 with stable disease and ten with progressive disease at study end. The most common drug-related adverse events were nausea (27%), abdominal pain (20%), weight loss (20%), and hyperglycemia (16%) and most were of mild or moderate severity. Pasireotide 600–900 μg s.c. bid was effective and generally well tolerated in controlling the symptoms of carcinoid syndrome in 27% of patients with advanced NET refractory or resistant to octreotide LAR therapy.
Search for other papers by Nele Garbrecht in
Google Scholar
PubMed
Search for other papers by Martin Anlauf in
Google Scholar
PubMed
Search for other papers by Anja Schmitt in
Google Scholar
PubMed
Search for other papers by Tobias Henopp in
Google Scholar
PubMed
Search for other papers by Bence Sipos in
Google Scholar
PubMed
Search for other papers by Andreas Raffel in
Google Scholar
PubMed
Search for other papers by Claus F Eisenberger in
Google Scholar
PubMed
Search for other papers by Wolfram T Knoefel in
Google Scholar
PubMed
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
Search for other papers by Christian Fottner in
Google Scholar
PubMed
Search for other papers by Thomas J Musholt in
Google Scholar
PubMed
Search for other papers by Anja Rinke in
Google Scholar
PubMed
Search for other papers by Rudolf Arnold in
Google Scholar
PubMed
Search for other papers by Uta Berndt in
Google Scholar
PubMed
Search for other papers by Ursula Plöckinger in
Google Scholar
PubMed
Search for other papers by Bertram Wiedenmann in
Google Scholar
PubMed
Search for other papers by Holger Moch in
Google Scholar
PubMed
Search for other papers by Philipp U Heitz in
Google Scholar
PubMed
Department of Pathology, Department of Pathology, Department of General, Department of Gastroenterology and Endocrinology, Department of Endocrinology, Department of General and Abdominal Surgery, Department of Gastroenterology and Endocrinology, Department of Hepatology and Gastroenterology, Department of Pathology, Institute of Pathology, University of Kiel, Michaelisstr. 11, 24105 Kiel, Germany
Search for other papers by Paul Komminoth in
Google Scholar
PubMed
Department of Pathology, Department of Pathology, Department of General, Department of Gastroenterology and Endocrinology, Department of Endocrinology, Department of General and Abdominal Surgery, Department of Gastroenterology and Endocrinology, Department of Hepatology and Gastroenterology, Department of Pathology, Institute of Pathology, University of Kiel, Michaelisstr. 11, 24105 Kiel, Germany
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Search for other papers by Günter Klöppel in
Google Scholar
PubMed
Somatostatin-producing neuroendocrine tumors (SOM-NETs) of the duodenum and pancreas appear to be heterogeneous. To determine their clinicopathological profiles, respective data were analyzed on a series of 82 duodenal and 541 pancreatic NETs. In addition, the clinical records of 821 patients with duodenal or pancreatic NETs were reviewed for evidence of a somatostatinoma syndrome. Predominant or exclusive expression of somatostatin was found in 21 (26%) duodenal and 21 (4%) pancreatic NETs. They were classified as sporadic (n=31) or neurofibromatosis type 1 (NF1)-associated duodenal NETs (n=3), gangliocytic paragangliomas (GCPGs; n=6), or poorly differentiated neuroendocrine carcinomas (pdNECs; n=2). In addition, five duodenal and four pancreatic SOM-NETs were found in five patients with multiple endocrine neoplasia type 1 (MEN1). Metastases occurred in 13 (43%) patients with sporadic or NF1-associated SOM-NETs, but in none of the duodenal or pancreatic MEN1-associated SOM-NETs or GCPGs. Sporadic advanced (stage IV) SOM-NETs were more commonly detected in the pancreas than in the duodenum. None of the patients (including the 821 patients for whom only the clinical records were reviewed) fulfilled the criteria of a somatostatinoma syndrome. Our data show that somatostatin expression is not only seen in sporadic NETs but may also occur in GCPGs, pdNECs, and hereditary NETs. Surgical treatment is effective in most duodenal and many pancreatic SOM-NETs. MEN1-associated SOM-NETs and GCPGs follow a benign course, while somatostatin-producing pdNECs are aggressive neoplasms. The occurrence of the so-called somatostatinoma syndrome appears to be extremely uncommon.